布鲁顿酪氨酸激酶抑制剂介导的出血机制及临床管理  

Mechanism and clinical management of Bruton's tyrosine kinase inhibitor-mediated bleeding

作　　者：宋丽霞 康虹阳 韩国将 刘洁[2] 范凌(综述)[2] 佟长青(审校)[2] Lixia Song;Hongyang Kang;Guojiang Han;Jie Liu;Ling Fan;Changqing Tong(Hebei North University,Zhangjiakou 075000,China;Department of Hematology,The First Affiliated Hospital of Hebei North Uni-versity,Zhangjiakou 075000,China)

机构地区：[1]河北北方学院,河北省张家口市075000 [2]河北北方学院附属第一医院血液科,河北省张家口市075000

出　　处：《中国肿瘤临床》2024年第14期737-741,共5页Chinese Journal of Clinical Oncology

摘　　要：布鲁顿酪氨酸激酶(Bruton's tyrosine kinase,BTK)抑制剂是治疗B细胞淋巴瘤的新型靶向药物,尤其在套细胞淋巴瘤(mantle cell lymphoma,MCL)、慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(chronic lymphocytic leukemia/small lymphocytic lymphoma,CLL/SLL)、华氏巨球蛋白血症(Waldenstr?m's macroglobulinaemia,WM)的治疗中显示出良好的疗效。随着BTK抑制剂在临床上的广泛使用,出血的不良反应逐渐显现。出血事件是由于BTK抑制剂的脱靶效应引起,在使用过程中通过多条信号通路来影响血小板功能,导致出血的发生。出血一旦发生将影响患者的治疗,严重会危机生命,应该加强出血的临床管理,本文就BTK抑制剂引起出血的作用机制及临床管理进行综述。Bruton's tyrosine kinase(BTK)inhibitors are novel drugs targeted for the treatment of B-cell lymphoma.BTK inhibitors have produced strong curative effects,especially for mantle cell lymphoma(MCL),chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SSL),and Waldenström's macroglobulinemia(WM).However,the adverse effect of bleeding has gradually been noted with the widespread use of BTK inhibitors in clinical practice.Bleeding events are caused by the off-target effects of BTK inhibitors,which affect platelet function through multiple signaling pathways during use.Bleeding affects patient treatment and threatens their quality of life.As such,the clinical management of bleeding should be strengthened.This paper provides a review of the mechanisms of action and clinical management of bleeding caused by BTK inhibitors.

关 键 词：BTK抑制剂 出血 不良事件 临床管理 

分 类 号：R730.5[医药卫生—肿瘤]